Prox1-CreERT2 (Jackson Laboratories, Strain #: 022075; Bar Harbor, ME, USA) and R26RtdTomato mice (Jackson Laboratories, Stock #: 007905) were crossed to generate Prox1-CreERT2; R26Rtdt mice, Prox1-CreERT2; R26RtdT mice at 8 weeks were i.p. injected within tamoxifen (100 mg/kg) to lineage label the lymphatic endothelial cells.
Prox1-CreERT2; R26RtdT mice were further bred with Pd-l1loxp/loxp mice (Jackson Laboratories, Strain #:036255) which have loxP sites flanking exons 2–3 of the Cd274 gene.
All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University. Mice were intranasally infected with PR8 (40 μL) at a dose of 150 PFU per mouse under tribromoethanol anesthesia. All infected mice were monitored, body weight was measured including initial timepoint.
Prox1-CreERT2; R26RtdT mice were further bred with Pd-l1loxp/loxp mice (Jackson Laboratories, Strain #:036255) which have loxP sites flanking exons 2–3 of the Cd274 gene.
All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University. Mice were intranasally infected with PR8 (40 μL) at a dose of 150 PFU per mouse under tribromoethanol anesthesia. All infected mice were monitored, body weight was measured including initial timepoint.